- DEPARTMENT SECTION: Biología Celular
- Name and code oin the Andalusian Research Plan (PAI): BIO-276
- Head of the PAI research group: José Manuel Villalba Montoro
Envejecimiento e intervenciones antienvejecimiento
Envejecimiento e intervenciones antienvejecimiento
- IP: José Manuel Villalba Montoro
- Location: Universidad de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Campus Rabanales, edificio Severo Ochoa 3ª planta, 14014-Córdoba, España
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. / 957 218 595
- IP:
José Manuel Villalba Montoro
- INVESTIGADORES:
María Isabel Burón Romero
José Antonio González Reyes
- PREDOCTORALES:
Luz Marina Sánchez Mendoza
Miguel Pérez Rodríguez
The research work of the group is focused on mitochondrial mechanisms involved in the physiological decline associated with aging in several tissues (liver, skeletal muscle, kidney, adipose tissue, etc). We investigate the effects of interventions with potential anti-aging properties, such as caloric restriction, diet supplementation with NAD + precursors (nicotinamide, nicotinamide riboside, nicotinamide mononucleotide), and overexpression or activation of NADH dehydrogenase cytochrome b 5 reductase (CYB5R3). Our research is preclinical, utilizing both cellular models and experimental animals (wild-type and transgenic mice). In the latter case, we are particularly interested in studying the role of the animals' gender in the response to anti-aging interventions. Our most recent research results have demonstrated an interaction between CYB5R3 overexpression and caloric restriction or nicotinamide riboside dietary supplementation, which can modulate the effects of these interventions, in a way that is both tissue- and sex-dependent. Techniques developed by the group include ultrastructural analysis using electron microscopy, determination of protein marker abundance through western blot, RNAseq, and determination of mRNA abundance through qRT-PCR. Additionally, we conduct cell and isolated mitochondria respirometry (SeaHorse), body composition assessments (magnetic resonance), and indirect calorimetry in metabolic chambers, as well as evaluations of physical and cognitive fitness in mice. We maintain a stable collaboration with Rafael de Cabo's group at the National Institute on Aging (NIA, NIH) in the United States. Additionally, we collaborate with the other two teams integrated into our group, contributing our expertise to elucidate the involvement of mitochondrial function in renal damage models (PI: Juan A. Moreno) and the therapeutic potential of NAD + precursors in autoimmune pathologies (PI: Carlos Pérez). We have established collaboration agreements with Chromadex, a world leader in the production of NAD + boosters.
Título: Activación de CYB5R3 y de la biosíntesis del NAD+ como nueva estrategia antienvejecimiento. Entidad y nº ref.: PID2021-126280OB-I00 Subvención: 120.000 € Duración: 2022-2025 Investigador ppal. José Manuel Villalba Montoro
- Autores (p.o. de firma): Sánchez-Mendoza LM, Pérez-Sánchez C, Rodríguez-López S, López-Pedrera C, de Cabo R, Burón MI, González-Reyes JA, and Villalba JM Título: Sex-specific metabolic adaptations in transgenic mice overexpressing cytochrome b 5 reductase-3 Ref. revista: Free Radic Biol Med (IF: 8.101) Libro Clave: A Volumen: 207 Páginas: 144-160 Fecha: 2023 D.O.I.: https://doi.org/10.1016/j.freeradbiomed.2023.07.012
- Autores (p.o. de firma): Hong X, Isern J, Campanario S, Perdiguero E, Ramírez-Pardo I, Segalés J, Hernansanz- Agustín P, Curtabbi A, Deryagin O, Pollán A, González-Reyes JA, Villalba JM, Sandri M, Serrano AL, Enríquez JA, Muñoz-Cánoves P Título: Mitochondrial dynamics maintain muscle stem cell regenerative competence throughout adult life by regulating metabolism and mitophagy Ref. revista: Cell Stem Cell (IF: 24.63) Libro Clave: A Volumen: 29(9): Páginas, inicial: 1298 final: 1314.e10 Fecha: 2022 D.O.I.: https://doi.org/10.1016/j.stem.2022.07.009
- Autores (p.o. de firma): Mitchell SJ, Madrigal-Matute J, Scheibye-Knudsen M, Fang E, Aon M, González-Reyes JA, Cortassa S, Kaushik S, Gonzalez-Freire M, Patel B, Wahl D, Ali A, Calvo-Rubio M, Burón MI, Guiterrez V, Ward TM, Palacios HH, Cai H, Frederick DW, Hine C, Broeskamp F, Habering L, Dawson J, Beasley TM, Wan J, Ikeno Y, Hubbard G, Becker KG, Zhang Y, Bohr VA, Longo DL, Navas P, Ferrucci L, Sinclair DA, Cohen P, Egan JM, Mitchell JR, Baur JA, Allison DB, Anson RM, Villalba JM, Madeo F, Cuervo AM, Pearson KJ, Ingram DK, Bernier M, de Cabo R. Título: Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice Ref. 1 revista: Cell Metab. 0 Libro Clave: A Volumen: 23(6) Páginas, inicial: 1093 final: 1112 Fecha: 2016 D.O.I.: http://dx.doi.org/10.1016/j.cmet.2016.05.027
- Autores (p.o. de firma): Miguel Calvo-Rubio; Mª Isabel Burón; Guillermo López-Lluch, Plácido Navas, Rafael de Cabo, Jon J. Ramsey, José M. Villalba and José A. González-Reyes Título: Dietary fat composition influences glomerular and proximal convoluted tubule cell structure and autophagic processes in kidneys from calorie restricted mice Ref. revista: Aging Cell Libro Clave: A Volumen: 15 Páginas, inicial: 477 final: 487 Fecha: 2016 D.O.I.: http://dx.doi.org/10.1111/acel.12451
Fisiopatología del daño renal y vascular
Fisiopatología del daño renal y vascular
- IP: Juan Antonio Moreno Gutiérrez
- Location: Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Campus de Excelencia Internacional Agroalimentario, CeiA3, Córdoba, Spain.
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. / 957 213 849
- Web: enlace
- RRSS: @juan_moreno_castro - LinkedIn
- IP:
Juan Antonio Moreno Gutiérrez
- INVESTIGADORES:
Lucía Beltrán Camacho
- PREDOCTORALES:
Mercedes Vallejo Mudarra
Cristina García Caballero
Renal and cardiovascular diseases are common pathologies associated with high mortality rates. Our group is investigating new pathogenic mechanisms involved in the development of these diseases to identify new molecules that can be used as potential prognostic biomarkers. We also aim to develop new therapeutic approaches against these pathological conditions. Specifically, we are interested in studying processes implicated in the progression from acute kidney failure to chronic kidney disease,glomerular diseases, hemolytic anemias, etc. To achieve these objectives, our group applyes techniques of cellular and molecular biology in cell cultures and samples from animal models and patients, such as flow cytometry, confocal microscopy, enzymatic activity assays, gene/protein expression analysis, etc).
Recently, we have observed that one of the mechanisms involved in the loss of renal function is the massive accumulation of hemoglobin, myoglobin, and other hemoproteins in the kidney. The massive accumulation of these hemoproteins in the kidney promotes acute renal injury and chronic kidney disease, as observed in patients with glomerula hematuria and massive/recurrent intravascular hemolysis (atypical hemolytic uremic syndrome, paroxysmal nocturn hemoglobinuria, and sickle cell disease).
We actively collaborate with numerous research groups (Jiménez Díaz Foundation, Autonomous University of Madrid, Complutense University of Madrid, Paris Diderot University, among others). Additionally, we are members of 2 COST actions, the Spanish Erythropathology Group, and the Spanish Acute Kidney Injury Group, European Network of Immunonephrology. In the last years, we have obtained competitive research projects funded by the Carlos III Health Institute (ISCIII), Junta de Andalucia, the Spanish Atherosclerosis Society, the Spanish Society of Nephrology, and the Iñigo Álvarez de Toledo Renal Foundation.
- PI20/00375. Mechanisms and therapeutic targets involved in the progression of Hb- associated renal damage. Proyectos de Investigación en Salud. Instituto de Salud Carlos III. IP: Juan Antonio Moreno. 01/01/2021-31/12/2024. 141.570 €.
- Papel del daño podocitario en el deterioro de la función renal inducido por la acumulación de hemoglobina en pacientes con anemia hemolítica intravascular. Grupo de Eritropatología. Sociedad Española de Hematología. 2023-2024. IP: Juan Antonio Moreno. 6000€.
- COST Action CA20121 - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). 2021-2025
- SEC/FEC-INV-CLI 21/031. Valor pronóstico de la hemólisis intravascular en pacientes con estenosis aórtica severa tratados con implante de válvula aórtica transcatéter. IP: Soledad Ojeda Pineda. Sociedad Española de Cardiología, 2021-2024. €15,000.
- PI23/00669. Acumulación de hemoproteínas como responsable de la pérdida aguda y crónica de la función renal. Caracterización de nuevos mecanismos de daño e identificación de posibles dianas terapéuticas. Proyectos de Investigación en Salud. Instituto de Salud Carlos III. IP: Juan Antonio Moreno. 01/01/2024-31/12/2026. 190.000 €.
- Guerrero-Hue M, Vallejo-Mudarra M, García-Caballero C, Córdoba-David GM, Palomino-Antolín A, Herencia C, Vendrell-Casana B, Rubio-Navarro A, Egido J, Blanco- Colio LM, Moreno JA. Tweak/Fn14 system is involved in rhabdomyolysis-induced acute kidney injury. Biomed Pharmacother. 2023 Dec 31;169:115925. doi: 10.1016/j.biopha.2023.115925. PMID: 38007933
- Rayego-Mateos S, Morgado-Pascual JL, García-Caballero C, Lazaro I, Sala-Vila A, Opazo- Rios L, Mas-Fontao S, Egido J, Ruiz-Ortega M, Moreno JA. Intravascular hemolysis triggers NAFLD characterized by a deregulation of lipid metabolism and lipophagy blockade. J Pathol 2023 Oct;261(2):169-183. doi: 10.1002/path.6161. PMID: 37555366
- Vázquez-Carballo C, Herencia C, Guerrero-Hue M, García-Caballero C, Rayego-Mateos S, Morgado-Pascual JL, Opazo-Rios L, González-Guerrero C, Vallejo-Mudarra M, Cortegano I, Gaspar ML, de Andrés B, Egido J, Moreno JA. Role of Toll-like receptor 4 in intravascular hemolysis-mediated injury. J Pathol 2022 Nov;258(3):236-249. doi: 10.1002/path.5995. PMID: 35903022.
- Guerrero-Hue M, García-Caballero C, Palomino-Antolín A, Rubio-Navarro A, Vázquez- Carballo C, Herencia C, Martín-Sanchez D, Farré-Alins V, Egea J, Cannata P, Praga M, Ortiz A, Egido J, Sanz AB, Moreno JA. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. FASEB J. 2019 Aug;33(8):8961-8975. doi: 10.1096/fj.201900077R. PMID: 31034781.
- Rubio-Navarro A, Sanchez-Niño MD, Guerrero-Hue M, García-Caballero C, Gutiérrez E, Yuste C, Sevillano Á, Praga M, Egea J, Román E, Cannata P, Ortega R, Cortegano I, de Andrés B, Gaspar ML, Cadenas S, Ortiz A, Egido J, Moreno JA. Podocytes are new cellular targets of haemoglobin-mediated renal damage. J Pathol. 2018 Mar;244(3):296-310. doi: 10.1002/path.5011. PMID: 29205354.
Alteraciones asociadas al metabolismo de NAD+
Alteraciones asociadas al metabolismo de NAD+
- IP: Carlos Pérez Sánchez
- Location: Dpto. de Biología Celular, Fisiología e Inmunología. Campus de Rabanales, Edificio Severo Ochoa, 3ª planta. 14014-Cordoba. Grupo GC05. IMIBIC. Avenida Menéndez Pidal S/N. 14004. Córdoba
- Contact:This email address is being protected from spambots. You need JavaScript enabled to view it.
- RRSS: @carlosps85
- IP: Carlos Pérez Sánchez
- PREDOCTORALES: Beatriz Vellón García
- Otros: 1 Técnico de laboratorio, 2 estudiantes trabajo fin de grado, 1 estudiante trabajo fin de master
La principal línea de investigación se enfoca en el estudio de las alteraciones asociadas al metabolismo de NAD + en el desarrollo y progresión de enfermedades sistémicas autoinmunes e inflamatorias crónicas, así como su modulación mediante potenciadores o precursores de NAD + .
Paralelamente se trabaja en la identificación nuevos biomarcadores diagnósticos, pronósticos y de respuesta a terapia en dichas patologías utilizando tecnologías ómicas de alto rendimiento y herramientas computacionales avanzadas.
- Evaluación preclínica de los precursores de NAD+ como nuevas herramientas terapéuticas en Enfermedades Reumáticas Inflamatorias Crónicas (PRECLINAD). Proyectos Generación de Conocimiento 2022. Ministerio de ciencia e innovación 2023-2026. 213.000 euros
- Suplementación con Nicotinamida como nueva estrategia terapéutica en pacientes con Artritis Reumatoide. Ministerio de ciencia e innovación. Proyectos de investigación clínica independiente. 2023-2026. 411.400 euros.
- Perez-Sanchez C, Escudero-Contreras A, Cerdó T, Sánchez-Mendoza LM, Llamas- Urbano A, la Rosa IA, Pérez-Rodriguez M, Muñoz-Barrera L, Del Carmen Abalos- Aguilera M, Barbarroja N, Calvo J, Ortega-Castro R, Ruiz-Vilchez D, Moreno JA, Burón MI, González-Reyes JA, Collantes-Estevez E, Lopez-Pedrera C, Villalba JM. Preclinical Characterization of Pharmacologic NAD+ Boosting as a Promising Therapeutic Approach in Rheumatoid Arthritis. Arthritis Rheumatol. 2023 Oct;75(10):1749-1761. doi: 10.1002/art.42528. Epub 2023 Jul 28. PMID: 37094367.
- Lopez-Pedrera C, Patiño-Trives AM, Cerdó T, Ortega-Castro R, Sanchez-Pareja I, Ibañez- Costa A, Muñoz-Barrera L, Ábalos-Aguilera MC, Ruiz-Vilchez D, Seguí Azpilcueta P, Espinosa M, Barbarroja N, Escudero-Contreras A, Castaño JP, Luque RM, Ortega R, Aguirre MA, Perez-Sanchez C. Splicing machinery is profoundly altered in systemic lupus erythematosus and antiphospholipid syndrome and directly linked to key clinical features. J Autoimmun. 2023 Feb;135:102990. doi: 10.1016/j.jaut.2022.102990. Epub 2023 Jan 6. PMID: 36621176.
- Perez-Sanchez C, Barbera Betancourt A, Lyons PA, Zhang Z, Suo C, Lee JC, McKinney EF, Modis LK, Ellson C, Smith KGC. miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease. J Exp Med. 2022 May 2;219(5):e20211366. doi: 10.1084/jem.20211366. Epub 2022 Apr 1. PMID: 35363256; PMCID: PMC8980842.
- Ibáñez-Costa A*, Perez-Sanchez C*, Patiño-Trives AM, Luque-Tevar M, Font P, Arias de la Rosa I, Roman-Rodriguez C, Abalos-Aguilera MC, Conde C, Gonzalez A, Pedraza- Arevalo S, Del Rio-Moreno M, Blazquez-Encinas R, Segui P, Calvo J, Ortega Castro R, Escudero-Contreras A, Barbarroja N, Aguirre MA, Castaño JP, Luque RM, Collantes- Estevez E, Lopez-Pedrera C. Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. Ann Rheum Dis. 2022 Jan;81(1):56-67. doi: 10.1136/annrheumdis-2021-220308. Epub 2021 Oct 8. PMID: 34625402; PMCID: PMC8762032.
- Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, Ábalos-Aguilera MC, Jiménez-Gómez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernández-Del Río L, González-Reyes JA, Segui P, Collantes-Estévez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, López-Pedrera C. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932. doi: 10.1161/ATVBAHA.117.309225. Epub 2017 Jul 6. PMID: 28684614.